Research into small amphibians has been stymied by limited means of tracking their movements, hindering conservation efforts. Harmonic direction finding technology, adapted from avalanche rescue ...

For the initial safety lead-in portion of the Phase 2 study, which involved 7 patients, all patients received the LP-300 drug candidate with pemetrexed and carboplatin intravenously2. Preliminary ...

-- Multiple chemically distinct, next-generation oral KIT inhibitors in exploratory toxicology studies; on track to nominate development candidate in 2023 CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE ...

BELTSVILLE, Md., May 3, 2023 /PRNewswire/ -- Reprocell USA, a CRO, has been awarded a contract to provide support for Lantern Pharma's (LTRN) Phase 2 clinical trial entitled "A Study of LP-300 With ...

Ongoing neuroscience research on psychedelic drugs like LSD and psilocybin is increasingly demonstrating the healing potential of these substances. In the case of LSD, researchers note in a recent ...

DALLAS--(BUSINESS WIRE)--Lantern Pharma (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug ...

-- Multiple chemically distinct, next-generation oral KIT inhibitors in exploratory toxicology studies; on track to nominate development candidate in 2023 The Company is initiating nonclinical studies ...